<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376763</url>
  </required_header>
  <id_info>
    <org_study_id>031-402-00129</org_study_id>
    <nct_id>NCT03376763</nct_id>
  </id_info>
  <brief_title>MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics</brief_title>
  <acronym>MAESTRO</acronym>
  <official_title>MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional, multicenter, open-label, 20 weeks study&#xD;
&#xD;
        -  To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena.&#xD;
&#xD;
        -  To identify efficacy and safety in switching from oral atypical antipsychotics other&#xD;
           than aripiprazole to Abilify Maintena&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We would like to evaluate the efficacy and safety when switching to Abilify Maintena&#xD;
      according to the approved indication of Abilify Maintena, for subjects who are taking oral&#xD;
      antipsychotic drugs. It is expected that this will serve as a basis for suggesting a&#xD;
      successful switching guideline from oral antipsychotics to Abilify Maintena, which can be&#xD;
      applicable in clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">December 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS total score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in PANSS total score from baseline to Week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in CGI-S (severity) from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mean CGI-I (improvement) score at Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS positive and negative subscale score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in PANSS positive and negative subscale score from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IAQ score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mean IAQ score at Week 16</description>
  </secondary_outcome>
  <other_outcome>
    <measure>study discontinuation rates</measure>
    <time_frame>16 weeks</time_frame>
    <description>Comparison the study discontinuation rates between Group 1 and Group 2</description>
  </other_outcome>
  <other_outcome>
    <measure>study discontinuation rates</measure>
    <time_frame>16 weeks</time_frame>
    <description>Comparison the study discontinuation rates in Group 2 depending on the other oral atypical antipsychotics</description>
  </other_outcome>
  <other_outcome>
    <measure>proportion of subjects who have more than 20% increased rating on the PANSS total score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Comparison the proportion of subjects who have more than 20% increased rating on the PANSS total score from baseline to Week 16 between Group 1and Group 2</description>
  </other_outcome>
  <other_outcome>
    <measure>proportion of subjects who have more than 20% increased rating on the PANSS total score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Comparison the proportion of subjects who have more than 20% increased rating on the PANSS total score from baseline to Week 16 in Group 2 depending on the other oral atypical antipsychotics</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Antipsychotics</condition>
  <condition>Long-Acting Injection</condition>
  <condition>LAI</condition>
  <condition>Aripiprazole</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abilify maintena</intervention_name>
    <description>Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>long-acting injectable aripiprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Subjects who voluntarily consented to participating in the clinical trial.&#xD;
&#xD;
          2. Male and female legally aged ≥19 and &lt; 65 years.&#xD;
&#xD;
          3. Subjects who were diagnosed of schizophrenia as defined by DSM diagnostic criteria,&#xD;
             and were diagnosed of schizophrenia for at least for 2 years prior to screening.&#xD;
&#xD;
          4. Subjects with all of the following schizophrenia clinical features:&#xD;
&#xD;
             A. Outpatient subjects, with no hospitalization for worsening of schizophrenia within&#xD;
             3 months prior to screening.&#xD;
&#xD;
             B. Subjects who have no more than a moderate rating on the PANSS total score≤80 C. 4&#xD;
             individual PANSS items, which are concerning to psychotic symptom (P2. conceptual&#xD;
             disorganization, P3. hallucinatory behavior, P6. suspiciousness/persecution, G9.&#xD;
             unusual thought content), score≤4.&#xD;
&#xD;
             D. CGI-S score ≤4 (moderately ill).&#xD;
&#xD;
          5. Subjects who take atypical antipsychotic drugs with the therapeutic effective dose (as&#xD;
             specified in each label) for schizophrenia treatment, and should be maintained on the&#xD;
             type and dose of the current antipsychotic drugs (including both typical and atypical&#xD;
             antipsychotic drugs) for at least 4 weeks prior to the screening.&#xD;
&#xD;
          6. Subjects who need antipsychotic treatment (other than clozapine), and would be stable&#xD;
             when switching to Abilify Maintena on the investigator's judgement.&#xD;
&#xD;
          7. Subjects must exhibit willingness, physiologic capability, and an educational level&#xD;
             sufficient to comply with all protocol procedures as per the investigator's judgment.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Subject who showed medically significant adverse events or intolerance with&#xD;
             aripiprazole during screening period or as prior experiences.&#xD;
&#xD;
          2. Subjects with a current DSM diagnostic criteria-based diagnosis other than&#xD;
             schizophrenia, including Schizoaffective disorder, major depressive disorder, bipolar&#xD;
             disorder, delirium, neurocognitive disorder due to Alzheimer's or similar diseases,&#xD;
             amnesia, borderline, paranoid, histrionic, schizotypal, schizoid, antisocial or other&#xD;
             cognitive or personality disorders.&#xD;
&#xD;
          3. Subjects with diseases of the central nervous system that may impact the assessment of&#xD;
             the psychotic symptoms as per investigator's opinion.&#xD;
&#xD;
          4. Subjects who have been treated with clozapine, electroconvulsive therapy (ECT) or&#xD;
             other long-acting injectable antipsychotic drugs within 3 months prior to the&#xD;
             screening.&#xD;
&#xD;
          5. Subjects who have been treated more than 2 oral antipsychotic drugs (including both&#xD;
             typical and atypical antipsychotic drugs) with the minimum therapeutic effective dose&#xD;
             (as specified in each label) for schizophrenia treatment at screening.&#xD;
&#xD;
             (e.g. Aripiprazole≥10 mg/day, Olanzapine≥10 mg/day, Risperidone≥2 mg/day, Quetiapine&#xD;
             ≥150 mg/day)&#xD;
&#xD;
          6. Subjects who have been treated with oral antipsychotic drugs (including both typical&#xD;
             and atypical antipsychotic drugs) exceeding maximum maintenance dose (as specified in&#xD;
             each label) at screening.&#xD;
&#xD;
             (e.g. Aripiprazole&gt;30 mg/day, Olanzapine&gt;20 mg/day, Risperidone &gt; 6 mg/day, Quetiapine&#xD;
             &gt; 750 mg/day)&#xD;
&#xD;
          7. Subjects with a significant risk of violent behavior or a significant risk of&#xD;
             committing suicide based on history or investigator's judgment.&#xD;
&#xD;
          8. Subjects had a history of seizures, neuroleptic malignant syndrome, clinically&#xD;
             significant tardive dyskinesia, or other medical condition that would expose them to&#xD;
             undue risk or interfere with study assessments.&#xD;
&#xD;
          9. Significant history of drug abuse disorder (excluding caffeine and nicotine, including&#xD;
             alcohol, as defined in DSM-5 substance use disorder or in the opinion of the&#xD;
             investigator) within the last 6 months prior to screening.&#xD;
&#xD;
         10. Subjects who participated in another interventional clinical trial within 30 days&#xD;
             prior to screening.&#xD;
&#xD;
         11. Pregnant or lactating women, or women of childbearing potential who are not willing to&#xD;
             or not able to use contraceptive methods (sexual abstinence; oral, implanted or&#xD;
             injection hormone contraceptive methods; intrauterine device or condom; barrier&#xD;
             contraceptive methods such as diaphragm and spermicide), accepted to avoid pregnancy&#xD;
             until the end of the clinical trial.&#xD;
&#xD;
         12. Subjects having any other clinically significant finding of the physical examination&#xD;
             or laboratory value that make investigator consider that it would be inappropriate to&#xD;
             participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Soo Kwon, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Konkuk University Chungju Hospital</name>
      <address>
        <city>Chungju</city>
        <state>Chungcheongbuk-do</state>
        <zip>27376</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gongju National Hospital</name>
      <address>
        <city>Gongju</city>
        <state>Chungcheongnam-do</state>
        <zip>32601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si,</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cha Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Uijeongbu ST. Mary'S Hospital</name>
      <address>
        <city>Uijeongbu Si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yong-In Mental Hospital</name>
      <address>
        <city>Yongin-si</city>
        <state>Gyeonggi-do</state>
        <zip>17089</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <state>Jeju-do</state>
        <zip>63241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35365</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hosipital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://mfds.go.kr/index.do?mid=1769&amp;seq=12790</url>
    <description>Clinical trial guideline for Antipsychotics; Ministry Food And Drug, 2015.09.</description>
  </link>
  <link>
    <url>http://www.korea.kr/archive/expDocView.do?docId=37547</url>
    <description>The survey of Mental Disorders in Korea; Ministry of Health and Welfare, 2016</description>
  </link>
  <link>
    <url>https://ezdrug.mfds.go.kr/#!CCBAA03F020</url>
    <description>Abilify Maintena Package Insert in Korea</description>
  </link>
  <link>
    <url>https://ezdrug.mfds.go.kr/#!CCBAA03F020</url>
    <description>Abilify Package Insert in Korea</description>
  </link>
  <reference>
    <citation>Aripiprazole Investigator Brochure, Version No. 20, 16 Aug 2016</citation>
  </reference>
  <results_reference>
    <citation>Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993 Feb;50(2):85-94.</citation>
    <PMID>8427558</PMID>
  </results_reference>
  <results_reference>
    <citation>Hong Kyu Ihm et al. Factors Related to Medication Adherence in Outpatients with Schizophrenia under More Than 5 Years of Treatment. J Korean Neuropsychiatr Assoc 2016; 55(4):397-406</citation>
  </results_reference>
  <results_reference>
    <citation>Hyun-Ku Kang, et al. Safety and Effectiveness of Long Acting Injectable Antipsychotic Paliperidone Palmitate Treatment in Schizophrenics: A 24-Week Open-Label Study. Korean J Biol Psychiatry 2013;20:111-117</citation>
  </results_reference>
  <results_reference>
    <citation>Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995 Mar;52(3):173-88.</citation>
    <PMID>7872841</PMID>
  </results_reference>
  <results_reference>
    <citation>Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001 Nov;158(11):1835-42.</citation>
    <PMID>11691689</PMID>
  </results_reference>
  <results_reference>
    <citation>Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012 May;73(5):617-24. doi: 10.4088/JCP.11m07530.</citation>
    <PMID>22697189</PMID>
  </results_reference>
  <results_reference>
    <citation>Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015 Oct;168(1-2):498-504. doi: 10.1016/j.schres.2015.07.007. Epub 2015 Jul 29.</citation>
    <PMID>26232241</PMID>
  </results_reference>
  <results_reference>
    <citation>Seockhoon Chung, Chang Yoon Kim. et al. Effectiveness and Tolerability of Long-Acting Risperidone：A 12 Weeks, Multi-center Switching Study from Oral Antipsychotics. Korean J Psychopharmacol 16/2:109-120, 2005</citation>
  </results_reference>
  <results_reference>
    <citation>Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014 Aug;205(2):135-44. doi: 10.1192/bjp.bp.113.134213. Epub 2014 Jun 12.</citation>
    <PMID>24925984</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aripiprazole</keyword>
  <keyword>Long-Acting Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

